News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
487,528 Results
Type
Article (8016)
Company Profile (141)
Press Release (479371)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166739)
Career Advice (304)
Deals (25739)
Drug Delivery (7)
Drug Development (52873)
Employer Resources (14)
FDA (9760)
Job Trends (8572)
News (238194)
Policy (17901)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (495)
Accelerated approval (29)
ADA (18)
Adcomms (1)
Allergies (100)
Alliances (33156)
ALS (117)
Alzheimer's disease (992)
Antibody-drug conjugate (ADC) (311)
Approvals (10458)
Artificial intelligence (354)
ASCO (160)
Autoimmune disease (233)
Automation (32)
Bankruptcy (263)
Belgium (4)
Best Places to Work (6957)
BIO (36)
Biologics (29)
BIOSECURE Act (1)
Biosimilars (123)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (12)
Bladder cancer (142)
Brain cancer (34)
Breast cancer (533)
Cancer (3923)
Cardiovascular disease (235)
Career advice (245)
Career pathing (1)
CAR-T (184)
CDC (1)
CDMO (28)
Celiac Disease (3)
Cell therapy (505)
Cervical cancer (36)
Clinical research (48334)
Collaboration (1339)
Commercialization (20)
Compensation (1605)
Complete response letters (36)
COVID-19 (768)
CRISPR (68)
C-suite (845)
Cystic fibrosis (89)
Data (6224)
Denatured (4)
Depression (108)
Dermatology (95)
Diabetes (377)
Diagnostics (4246)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (167)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (174)
Earnings (73846)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88544)
Executive appointments (733)
Eye disease (3)
FDA (12636)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (19)
Frontotemporal dementia (25)
Funding (989)
Gene editing (131)
Generative AI (13)
Gene therapy (346)
GLP-1 (307)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9382)
Hematology (94)
HIV (56)
Huntington's disease (25)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (73)
Immunology and inflammation (113)
Immuno-oncology (67)
Indications (177)
Infectious disease (969)
Inflammatory bowel disease (139)
Inflation Reduction Act (4)
Influenza (87)
Intellectual property (269)
Interviews (41)
IPO (12397)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (18)
Kidney disease (66)
Layoffs (59)
Legal (5195)
Licensing (41)
Liver cancer (46)
Longevity (23)
Lung cancer (564)
Lung diease (8)
Lymphoma (266)
Machine learning (29)
Management (3)
Manufacturing (608)
Marketing (16)
MASH (121)
Medical affairs (2)
Medical device (8707)
Medtech (8881)
Mergers & acquisitions (14446)
Metabolic disorders (760)
mRNA (70)
Multiple sclerosis (110)
Multispecific (2)
NASH (4)
Netherlands (1)
Neurodegenerative disease (237)
Neuropsychiatric disorders (40)
Neuroscience (1920)
Neurotech (1)
NextGen: Class of 2026 (3150)
Non-profit (844)
Obesity (239)
Opinion (10)
Ovarian cancer (176)
Pain (185)
Pancreatic cancer (225)
Parkinson's disease (215)
Partnered (12)
Patents (521)
Patient advocacy (2)
Patient recruitment (547)
Patient selection (33)
Peanut (33)
People (41488)
Peptides (13)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15595)
Phase 2 (21597)
Phase 3 (14571)
Pipeline (8245)
Policy (18)
Postmarket research (1570)
Preclinical (6583)
Press Release (34)
Prostate cancer (202)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (618)
Real estate (3024)
Recruiting (6)
Regenerative medicine (11)
Regulatory (15144)
Reports (23)
Research institute (590)
Resumes & cover letters (45)
Rett syndrome (45)
RNA editing (8)
RSV (49)
Schizophrenia (109)
Series A (173)
Series B (126)
Service/supplier (5)
Sickle cell disease (64)
Spinal muscular atrophy (92)
Sponsored (5)
Startups (2021)
Stem cells (1)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (54)
Tariffs (1)
Vaccines (346)
Venture capital (17)
Weight loss (76)
Wet AMD (3)
Women's health (96)
Date
Today (77)
Last 7 days (391)
Last 30 days (1538)
Last 365 days (19164)
2026 (15159)
2025 (19251)
2024 (22988)
2023 (26539)
2022 (34588)
2021 (37167)
2020 (33469)
2019 (23257)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24264)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (231)
Alabama (80)
Alaska (2)
Arizona (318)
Arkansas (12)
Asia (18026)
Australia (2116)
California (12766)
Canada (3337)
China (565)
Colorado (521)
Connecticut (444)
Delaware (221)
Europe (24770)
Florida (1919)
Georgia (404)
Hawaii (3)
Idaho (46)
Illinois (763)
India (57)
Indiana (330)
Iowa (18)
Japan (445)
Kansas (104)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1266)
Massachusetts (8349)
Michigan (321)
Minnesota (589)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (131)
New Hampshire (60)
New Jersey (2808)
New Mexico (12)
New York (2991)
North Carolina (1353)
North Dakota (4)
Northern California (6456)
Ohio (302)
Oklahoma (14)
Oregon (17)
Pennsylvania (2375)
Puerto Rico (24)
Rhode Island (30)
South America (407)
South Carolina (80)
South Dakota (1)
Southern California (5319)
Tennessee (128)
Texas (2109)
United States (41369)
Utah (387)
Vermont (1)
Virginia (165)
Washington D.C. (39)
Washington State (982)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
487,528 Results for "neurosigma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
September 25, 2026
·
10 min read
Press Releases
NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD
July 21, 2026
·
5 min read
Press Releases
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
December 16, 2025
·
3 min read
Biotech Beach
NeuroSigma Establishes Singapore Subsidiary
NeuroSigma, Inc. announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation, representing NeuroSigma’s first foreign subsidiary.
July 12, 2023
·
3 min read
Press Releases
NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
November 3, 2025
·
3 min read
Policy
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
NeuroSigma announced that the U.S. Food and Drug Administration cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder.
January 18, 2024
·
2 min read
Biotech Beach
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation Monarch eTNS System™ (Monarch 2.0).
November 7, 2023
·
1 min read
Biotech Beach
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products.
October 3, 2023
·
2 min read
Press Releases
NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders
January 22, 2025
·
2 min read
Business
NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced the commencement of a strategic digital marketing partnership with Data360, a leading provider of targeted, online marketing for the healthcare industry.
January 31, 2023
·
3 min read
1 of 48,753
Next
